Back to Search
Start Over
Acute Liver Failure following a Single Dose of Atezolizumab, as Assessed for Causality Using the Updated RUCAM
- Source :
- Case Reports in Gastrointestinal Medicine, Vol 2022 (2022)
- Publication Year :
- 2022
- Publisher :
- Wiley, 2022.
-
Abstract
- Immune checkpoint inhibitors have become major therapeutic agents in oncology over the last few years. However, they are associated with a variety of potentially severe autoimmune phenomena. We present a patient with advanced adenocarcinoma of the lung, who presented with acute liver injury two weeks following his first treatment with atezolizumab, rapidly deteriorating to fulminant liver failure. A thorough evaluation of infectious, vascular, metabolic, and autoimmune etiologies did not yield any results. Liver pathology was nonspecific. Using RUCAM as a causality assessment method indicated probable connection between atezolizumab and liver damage. To our knowledge, this is the first documented report of a patient developing acute liver failure shortly after immune checkpoint inhibitor initiation.
- Subjects :
- Diseases of the digestive system. Gastroenterology
RC799-869
Subjects
Details
- Language :
- English
- ISSN :
- 20906536
- Volume :
- 2022
- Database :
- Directory of Open Access Journals
- Journal :
- Case Reports in Gastrointestinal Medicine
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.2331245dc7f74a1e80af41f935fc3c3b
- Document Type :
- article
- Full Text :
- https://doi.org/10.1155/2022/5090200